INFO & CONTACTS:  +39 02 2390 1

A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS RIBOCICLIB PLUS FULVESTRANT VERSUS PLACEBO PLUS RIBOCICLIB PLUS FULVESTRANT IN PATIENTS WITH ENDOCRINE-RESISTANT HORMONE-RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WITH CHROMOSOME 8P LOSS AND WITHOUT A PIK3CA MUTATION (PROTOCOL NUMBER: CO46274)

Phase: Phase II clinical trials

Principal Investigator: Prof. Vernieri Claudio

Main Facility: Oncologia Medica 1

Drug: Inavolisib + Fulvestrant + Ribociclib vs Placebo + Fulvestrant + Ribociclib

Pathologies: Breast cancer

ClinicalTrials.gov: Read the details about clinical trials

A randomized, multicenter, double-blind Phase 2 clinical trial using the investigational treatment Inavolisib + Fulvestrant + Ribociclib versus Placebo + Fulvestrant + Ribociclib in patients with HR+, HER2- locally advanced, unresectable and/or metastatic breast cancer. The study will enroll patients whose breast cancer does not harbor a PIK3CA mutation but has loss of chromosome 8p (i.e., loss of chr8p).

Last update: 14/07/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe